Australian Clinical Labs Ltd 2023 AR2
The report highlights Australian Clinical Labs' (ACL) performance for the fiscal year 2023, focusing on its transition to a post-COVID environment and core business growth. Key achievements include delivering over 9 million pathology episodes, generating $697.1 million in revenue, and expanding digital pathology referrals to 19%. On the ESG front, ACL reduced carbon emissions from 1.4kg to 1.06kg CO2 per episode, decreased its Lost Time Injury Frequency Rate to 3.78, and increased female representation to 33% on the Board and 63.8% in management. Additionally, the company initiated its Reflect Reconciliation Action Plan and achieved a significant reduction in styrofoam waste.
Company: Australian Clinical Labs Ltd
Sector: Health Care
Country: Australia
Year: 2023
Type: AR2
Pages: 120
Back to company
Australian Clinical Labs Ltd
Annual Report
The report highlights Australian Clinical Labs' (ACL) performance for the fiscal year 2023, focusing on its transition to a post-COVID environment and core business growth. Key achievements include delivering over 9 million pathology episodes, generating $697.1 million in revenue, and expanding digital pathology referrals to 19%. On the ESG front, ACL reduced carbon emissions from 1.4kg to 1.06kg CO2 per episode, decreased its Lost Time Injury Frequency Rate to 3.78, and increased female representation to 33% on the Board and 63.8% in management. Additionally, the company initiated its Reflect Reconciliation Action Plan and achieved a significant reduction in styrofoam waste.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jul 1, 2022 - Jun 30, 2023
Fiscal Year
2023
Published
Oct 23, 2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees